Tag: rna targeting small molecule drug discovery market drivers

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

RNA Targeting Small Molecule Drug Discovery Market Size Forecast: How Big Could The Market Get By 2030?

The rna targeting small molecule drug discovery market has experienced substantial expansion in recent years. It will grow from $2.13 billion in 2025 to $2.6 billion in 2026 at a compound annual growth rate (CAGR) of 22.3%. The historical increase in this market can be attributed to several factors, including the limited druggability of protein targets, an escalating prevalence of genetic disorders, advancements in rna biology research, increased academic-industry collaborations, and the early successes of rna-based therapeutics.

The rna targeting small molecule drug discovery market size is projected to experience rapid expansion in the coming years. This market is anticipated to reach $6.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.5%. Factors driving this growth during the forecast period include the advent of AI-enabled rna target identification, a rise in precision medicine investments, the broadening of rna therapeutics pipelines, advancements in rna delivery technologies, and favorable regulatory backing for new treatment approaches. Key trends expected within the forecast timeframe encompass AI-powered rna structure prediction, an increase in rna-targeted oncology pipelines, progress in rna-specific small molecule libraries, enhanced rna binding selectivity and specificity, and the incorporation of multi-omics into rna drug discovery processes.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=54719454&type=smp&name=RNA%20Targeting%20Small%20Molecule%20Drug%20Discovery%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

RNA Targeting Small Molecule Drug Discovery Market Demand Drivers: What’s Powering Industry Growth?

The RNA-targeted small-molecule drug discovery market is projected to grow due to the increasing occurrence of cancer, genetic disorders, and viral infections. Cancer is defined as a collection of diseases characterized by the uncontrolled multiplication of cells within the body. Viral infections pertain to illnesses caused by viruses, which are microscopic infectious agents capable of replicating only inside the living cells of organisms. RNA targeting-based drug discovery offers a method to treat cancer, genetic disorders, and viral infections, as these conditions are associated with genes and impaired genetic material, which can be addressed by drugs developed using RNA targeting-based approaches. For instance, in February 2024, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, revealed an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are anticipated to climb by 77%, reaching over 35 million annually. Thus, the rising prevalence of cancer, genetic disorders, and viral infections is a key driver for the growth of the RNA-targeted small-molecule drug discovery market.

RNA Targeting Small Molecule Drug Discovery Market Breakdown By Product Type And Application

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

RNA Targeting Small Molecule Drug Discovery Market Innovation Trends: What Developments Are Reshaping The Industry?

Leading companies in the RNA-targeting small-molecule drug discovery market are implementing innovative platforms, including software-as-a-service platforms, to gain a competitive edge. Software-as-a-service (SaaS) is defined as a software distribution model where applications are hosted by a third-party vendor and are accessible to customers via the Internet. For example, in December 2023, the US-based science and technology company Merck & Co. Inc. launched AIDDISON. This platform suggests optimal synthesis routes for selected medications. This novel approach has the potential to generate significant cost savings in the drug discovery process and markedly improve the success rate for introducing new medicines to patients. By bridging the divide between virtual molecular design and real-world manufacturability, the platform elevates the success rate of delivering innovative treatments to patients by extracting crucial insights from vast datasets. This advanced AI system integrates computer-aided drug design, machine learning, and generative AI to expedite the medication development timeline.

RNA Targeting Small Molecule Drug Discovery Market Company Landscape And Competitive Strategy

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

View The Full RNA Targeting Small Molecule Drug Discovery Market Report:

https://thebusinessresearchcompany.com/report/RNA-targeting-small-molecule-drug-discovery-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

RNA Targeting Small Molecule Drug Discovery Market Geographic Analysis: Where Is Demand Accelerating Fastest?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

RNA Targeting Small Molecule Drug Discovery Market Revenue Growth Supported By A CAGR Of 6.04% Through 2030

The market for RNA-targeting small molecule drug discovery has experienced rapid expansion in recent years. Its value is projected to increase from $2.13 billion in 2025 to $2.6 billion in 2026, reflecting a compound annual growth rate (CAGR) of 22.3%. This historical growth has been driven by several factors, including the restricted druggability of protein targets, a growing incidence of genetic disorders, progress in RNA biology research, increased partnerships between academia and industry, and early achievements in RNA-based therapeutics.

The anticipated trajectory for the market focused on small molecule drugs targeting RNA indicates a period of substantial expansion in the coming years. By 2030, projections place its valuation at $6.04 billion, reflecting a compound annual growth rate of 23.5%. This forecasted growth is fueled by several contributing factors, including the identification of RNA targets through artificial intelligence, heightened investment directed toward precision medicine, an expanding pipeline of RNA-based therapeutics, advancements in delivery mechanisms for these molecules, and a supportive regulatory environment for novel therapeutic approaches. Key trends shaping this forward-looking period encompass AI-powered predictions of RNA structures, a growing number of oncology-focused drugs targeting RNA sequences, progress in constructing specialized small molecule libraries for RNA, enhancements in how these molecules bind with specificity and selectivity, and the integration of multi-omic data into the drug discovery process for RNA.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

RNA Targeting Small Molecule Drug Discovery Market Expansion Drivers: What Is Shaping Future Growth?

The rising incidence of cancer, genetic disorders, and viral infections is anticipated to drive expansion in the RNA-targeted small-molecule drug discovery market moving forward. Cancer encompasses a range of diseases marked by the abnormal and uncontrolled proliferation of cells within the body. Viral infections are those caused by viruses—tiny infectious entities that can only multiply inside the cells of living hosts. RNA-targeted drug discovery is employed to address cancer, genetic disorders, and viral infections because these conditions are associated with genes and defective genetic material, which can be managed through medications developed via RNA-targeting approaches. As an example, in February 2024, a report from the World Health Organization (WHO), an intergovernmental body based in Switzerland, indicated that approximately 20 million new cancer cases and 9.7 million deaths occurred worldwide in 2022. Lung cancer was the most prevalent, accounting for 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, the number of new cancer cases is projected to increase by 77%, reaching over 35 million annually. Consequently, the growing prevalence of cancer, genetic disorders, and viral infections is fueling the growth of the RNA-targeted small-molecule drug discovery market.

RNA Targeting Small Molecule Drug Discovery Market Segment Landscape And Growth Potential

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

RNA Targeting Small Molecule Drug Discovery Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Key players in the RNA-targeting small-molecule drug discovery sector are advancing unique platforms, including software-as-a-service models, to strengthen their market positions. The software-as-a-service (SaaS) framework operates as a distribution method where applications are managed by an external provider and offered to users via the internet. A notable example is Merck & Co. Inc., a United States-based science and technology firm, which released AIDDISON in December 2023. This platform identifies optimal synthetic approaches for these chosen compounds, potentially leading to significant reductions in expenses for the drug development process while substantially enhancing the likelihood of introducing new therapies to patients. By closing the gap between digital molecular design and tangible production feasibility, the system elevates the success rate of bringing innovative therapies to individuals by uncovering hidden patterns from extensive data sets. To speed up the medication creation process, this advanced artificial intelligence system combines computational drug design, machine learning methodologies, and generative AI techniques.

RNA Targeting Small Molecule Drug Discovery Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Access The Complete RNA Targeting Small Molecule Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

RNA Targeting Small Molecule Drug Discovery Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The RNA Targeting Small Molecule Drug Discovery Market By 2030 Based On Its 2026 Value?

The rna targeting small molecule drug discovery market size has seen significant expansion in recent years. It is anticipated to increase from $2.13 billion in 2025 to $2.6 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.3%. The growth observed in previous periods is attributable to the constrained druggability of protein targets, a rising incidence of genetic disorders, developments in rna biology research, an increase in academic-industry collaborations, and the initial successes of rna-based therapeutics.

The rna targeting small molecule drug discovery market is projected to experience significant expansion in the coming years, with its size expected to reach $6.04 billion by 2030, driven by a compound annual growth rate (CAGR) of 23.5%. This growth throughout the forecast period can be attributed to factors such as AI-enabled RNA target identification, increased investment in precision medicine, the broadening of RNA therapeutics pipelines, advancements in RNA delivery technologies, and regulatory support for novel therapeutic modalities. Prominent trends anticipated during this period include AI-driven RNA structure prediction, the expansion of RNA-targeted oncology pipelines, progress in developing RNA-specific small molecule libraries, enhanced RNA binding selectivity and specificity, and the integration of multi-omics approaches in RNA drug discovery.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Which Growth Drivers Are Expected To Support The RNA Targeting Small Molecule Drug Discovery Market Forward?

The projected expansion of the RNA-targeted small-molecule drug discovery market is anticipated to be driven by the rising incidence of cancer, genetic disorders, and viral infections. Cancer encompasses a range of illnesses defined by the uncontrolled proliferation of cells within the body. Viral infections are conditions resulting from viruses, which are microscopic infectious entities capable of replicating solely within the living cells of organisms. RNA targeting-based drug discovery offers therapeutic solutions for cancer, genetic disorders, and viral infections. This is because these conditions are associated with genes and impaired genetic material, making them amenable to treatment through drugs formulated with RNA targeting-based approaches. For example, a report released in February 2024 by the World Health Organization (WHO), an intergovernmental body located in Switzerland, indicated an estimated 20 million new cancer diagnoses and 9.7 million fatalities worldwide in 2022. Among these, Lung cancer was identified as the most prevalent, accounting for 2.5 million new cases (12.4%). It was succeeded by female breast cancer with 2.3 million cases (11.6%), colorectal cancer at 1.9 million cases (9.6%), prostate cancer registering 1.5 million cases (7.3%), and stomach cancer with 970,000 cases (4.9%). Projections suggest that by 2050, the incidence of new cancer cases will escalate by 77%, surpassing 35 million each year. Consequently, the escalating occurrence of cancer, genetic disorders, and viral infections serves as a key impetus for the expansion of the RNA-targeted small-molecule drug discovery market.

What Are The Major Segment Categories Within The RNA Targeting Small Molecule Drug Discovery Market?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

What Trends Are Shaping The RNA Targeting Small Molecule Drug Discovery Market Structure?

Major companies operating in the RNA-targeting small-molecule drug discovery market are developing innovative platforms, such as software-as-a-service models, to enhance their market position. Software-as-a-service (SaaS) represents a software distribution framework where applications are hosted by a third-party provider and made available to users over the Internet. For instance, in December 2023, Merck & Co. Inc., a US-based science and technology company, launched AIDDISON. This platform proposes the most effective methods for synthesizing specific medications. This novel approach could lead to significant cost reductions in the drug discovery process and substantially improve the success rate of bringing new treatments to patients. By connecting virtual molecular design with real-world manufacturability, the platform increases the likelihood of delivering innovative therapies to patients by extracting hidden insights from large datasets. To expedite the medication development process, this advanced AI system integrates computer-aided drug design, machine learning, and generative AI.

Which Organizations Are Involved In The RNA Targeting Small Molecule Drug Discovery Market?

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Access The Complete RNA Targeting Small Molecule Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Which Region Leads The RNA Targeting Small Molecule Drug Discovery Market By Size?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access RNA Targeting Small Molecule Drug Discovery Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The RNA Targeting Small Molecule Drug Discovery Market Expected To Reach Based On Its 2026 Value?

The rna targeting small molecule drug discovery market has seen substantial expansion in recent years. This market is set to increase from $2.13 billion in 2025 to $2.6 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.3%. The historical period’s growth can be linked to the restricted druggability of protein targets, a rising occurrence of genetic disorders, progress in rna biology research, an increase in academic-industry collaborations, and the early achievements of rna-based therapeutics.

The rna targeting small molecule drug discovery market size is projected to experience substantial growth in the coming years. This market is expected to expand to $6.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.5%. The projected increase during this period stems from advancements such as AI-enabled rna target identification, heightened investment in precision medicine, the expansion of rna therapeutics pipelines, enhanced rna delivery technologies, and supportive regulatory frameworks for innovative modalities. Prominent trends anticipated within this forecast timeframe include AI-driven rna structure prediction, the expansion of rna-targeted oncology pipelines, improvements in rna-specific small molecule libraries, better rna binding selectivity and specificity, and the integration of multi-omics in rna drug discovery efforts.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Which Key Drivers Are Affecting The RNA Targeting Small Molecule Drug Discovery Market Development?

The RNA-targeted small-molecule drug discovery market is projected to expand due to the rising prevalence of cancer, genetic disorders, and viral infections. Cancer is a group of diseases marked by uncontrolled cell proliferation, while viral infections are caused by tiny infectious agents, viruses, that replicate solely inside living cells. RNA targeting-based drug discovery is utilized to treat these conditions because they involve genes and malfunctioning genetic material, making them amenable to treatment through RNA targeting methods. For example, in February 2024, a report from the Switzerland-based World Health Organization (WHO) revealed an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most frequent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are anticipated to increase by 77%, exceeding 35 million annually. Consequently, the increasing occurrence of cancer, genetic disorders, and viral infections serves as a key driver for the growth of the RNA-targeted small-molecule drug discovery market.

How Is Segmentation Applied In The RNA Targeting Small Molecule Drug Discovery Market Segment Analysis?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Which Trends Are Shaping Growth In The RNA Targeting Small Molecule Drug Discovery Market?

Major companies in the RNA-targeting small-molecule drug discovery market are developing innovative platforms, such as software-as-a-service (SaaS) solutions, to gain a competitive edge. SaaS is a software distribution model where applications are hosted by a third-party provider and delivered to customers over the Internet. For instance, in December 2023, the U.S.-based science and technology company Merck & Co. Inc. launched AIDDISON. This platform proposes the most effective methods for synthesizing selected medications. This innovative strategy could lead to significant cost reductions in the drug discovery process and greatly enhance the success rate of introducing new medicines to patients. By connecting virtual molecular design with real-world manufacturability, the platform improves the success rate of delivering cutting-edge treatments to patients through extracting concealed insights from vast datasets. To accelerate the medication development process, this novel AI system integrates computer-aided drug design, machine learning, and generative AI.

Who Are The Companies Participating In The RNA Targeting Small Molecule Drug Discovery Market Environment?

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Get The Full RNA Targeting Small Molecule Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Which Geographic Region Dominates The RNA Targeting Small Molecule Drug Discovery Market?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized RNA Targeting Small Molecule Drug Discovery Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The RNA Targeting Small Molecule Drug Discovery Market Expected To Reach Based On Its 2026 Value?

The rna targeting small molecule drug discovery market has seen substantial expansion in recent years. This market is set to increase from $2.13 billion in 2025 to $2.6 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.3%. The historical period’s growth can be linked to the restricted druggability of protein targets, a rising occurrence of genetic disorders, progress in rna biology research, an increase in academic-industry collaborations, and the early achievements of rna-based therapeutics.

The rna targeting small molecule drug discovery market size is projected to experience substantial growth in the coming years. This market is expected to expand to $6.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.5%. The projected increase during this period stems from advancements such as AI-enabled rna target identification, heightened investment in precision medicine, the expansion of rna therapeutics pipelines, enhanced rna delivery technologies, and supportive regulatory frameworks for innovative modalities. Prominent trends anticipated within this forecast timeframe include AI-driven rna structure prediction, the expansion of rna-targeted oncology pipelines, improvements in rna-specific small molecule libraries, better rna binding selectivity and specificity, and the integration of multi-omics in rna drug discovery efforts.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Which Key Drivers Are Affecting The RNA Targeting Small Molecule Drug Discovery Market Development?

The RNA-targeted small-molecule drug discovery market is projected to expand due to the rising prevalence of cancer, genetic disorders, and viral infections. Cancer is a group of diseases marked by uncontrolled cell proliferation, while viral infections are caused by tiny infectious agents, viruses, that replicate solely inside living cells. RNA targeting-based drug discovery is utilized to treat these conditions because they involve genes and malfunctioning genetic material, making them amenable to treatment through RNA targeting methods. For example, in February 2024, a report from the Switzerland-based World Health Organization (WHO) revealed an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most frequent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are anticipated to increase by 77%, exceeding 35 million annually. Consequently, the increasing occurrence of cancer, genetic disorders, and viral infections serves as a key driver for the growth of the RNA-targeted small-molecule drug discovery market.

How Is Segmentation Applied In The RNA Targeting Small Molecule Drug Discovery Market Segment Analysis?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Which Trends Are Shaping Growth In The RNA Targeting Small Molecule Drug Discovery Market?

Major companies in the RNA-targeting small-molecule drug discovery market are developing innovative platforms, such as software-as-a-service (SaaS) solutions, to gain a competitive edge. SaaS is a software distribution model where applications are hosted by a third-party provider and delivered to customers over the Internet. For instance, in December 2023, the U.S.-based science and technology company Merck & Co. Inc. launched AIDDISON. This platform proposes the most effective methods for synthesizing selected medications. This innovative strategy could lead to significant cost reductions in the drug discovery process and greatly enhance the success rate of introducing new medicines to patients. By connecting virtual molecular design with real-world manufacturability, the platform improves the success rate of delivering cutting-edge treatments to patients through extracting concealed insights from vast datasets. To accelerate the medication development process, this novel AI system integrates computer-aided drug design, machine learning, and generative AI.

Who Are The Companies Participating In The RNA Targeting Small Molecule Drug Discovery Market Environment?

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Get The Full RNA Targeting Small Molecule Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Which Geographic Region Dominates The RNA Targeting Small Molecule Drug Discovery Market?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized RNA Targeting Small Molecule Drug Discovery Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The RNA Targeting Small Molecule Drug Discovery Market By The End Of 2030?

The rna targeting small molecule drug discovery market size has seen substantial growth in recent years. It is anticipated to expand from $2.13 billion in 2025 to $2.6 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.3%. The historical expansion can be linked to the restricted druggability of protein targets, a rising occurrence of genetic disorders, advancements in rna biology research, an increase in academic-industry partnerships, and the initial achievements of rna-based therapeutics.

The rna targeting small molecule drug discovery market size is projected to experience rapid expansion over the coming years. By 2030, this market is anticipated to reach $6.04 billion, exhibiting a compound annual growth rate (CAGR) of 23.5%. Several factors are driving this anticipated growth, including AI-enabled identification of rna targets, a rise in precision medicine investments, the broadening of rna therapeutics pipelines, advancements in rna delivery methods, and supportive regulations for new therapeutic approaches. Key developments foreseen during this period encompass AI-powered rna structure prediction, the broadening of oncology pipelines focused on rna, enhancements in small molecule libraries tailored for rna, greater selectivity and specificity in rna binding, and the incorporation of multi-omics data into rna drug discovery processes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Which Market Drivers Are Supporting The Expansion Of The RNA Targeting Small Molecule Drug Discovery Market?

The rising incidence of cancer, genetic ailments, and viral illnesses is projected to drive expansion within the RNA-targeted small-molecule drug discovery market in the future. Cancer encompasses a range of conditions defined by unchecked cellular proliferation within the organism. Viral infections are those stemming from viruses, which are minute infectious agents capable of replication solely within the cells of living hosts. RNA targeting-based drug discovery offers therapeutic approaches for cancer, genetic disorders, and viral infections, given that these conditions involve genes and dysfunctional genetic material that can be addressed by medications formulated through RNA targeting-based techniques. As an illustration, a report released in February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental body, estimated 20 million new cancer diagnoses and 9.7 million fatalities worldwide in 2022. The most prevalent type was lung cancer, accounting for 2.5 million new instances (12.4%), succeeded by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). Projections indicate that by 2050, new cancer cases will increase by 77%, exceeding 35 million each year. Consequently, the expanding occurrence of cancer, genetic disorders, and viral infections fuels the expansion of the RNA-targeted small-molecule drug discovery market.

Which Segment Classifications Shape The RNA Targeting Small Molecule Drug Discovery Market?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

How Are Trends Impacting The RNA Targeting Small Molecule Drug Discovery Market?

Leading companies within the RNA-targeting small-molecule drug discovery market are implementing advanced platforms, such as software-as-a-service models, to secure a competitive advantage. Software-as-a-service (SaaS) is a system for software delivery where a third-party hosts applications and provides them to customers via the internet. As an illustration, in December 2023, Merck & Co. Inc., a US-based science and technology firm, introduced AIDDISON. This platform offers guidance on the optimal synthesis methods for selected medications. This innovative approach has the potential to significantly reduce costs in the drug discovery process and enhance the likelihood of successfully introducing new treatments to patients. By connecting virtual molecular design with practical manufacturing capabilities, the platform boosts the success rate of delivering groundbreaking therapies by uncovering valuable insights from extensive datasets. To expedite the development of medications, this novel artificial intelligence system combines computer-aided drug design, machine learning, and generative AI.

Which Companies Are Expanding Their Footprint In The RNA Targeting Small Molecule Drug Discovery Market?

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Read the full rna targeting small molecule drug discovery market report here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

How Is The RNA Targeting Small Molecule Drug Discovery Market Distributed Across Key Geographic Regions?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored RNA Targeting Small Molecule Drug Discovery Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the rna targeting small molecule drug discovery market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the RNA Targeting Small Molecule Drug Discovery Market be in 2030 compared with 2026?

The rna targeting small molecule drug discovery market has witnessed significant expansion over recent years. It is projected to increase from $2.13 billion in 2025 to $2.6 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.3%. This historical growth can be attributed to several factors including the constrained druggability of protein targets, the increasing occurrence of genetic disorders, breakthroughs in rna biology research, an escalation in academic-industry partnerships, and the initial successful outcomes of rna-based therapeutics.

The rna targeting small molecule drug discovery market is projected for rapid expansion in the coming years, reaching $6.04 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 23.5%. This projected growth during the forecast period is fueled by several factors, including AI-enabled rna target identification, rising investments in precision medicine, the broadening of rna therapeutics pipelines, advancements in rna delivery technologies, and favorable regulatory backing for new modalities. Key trends anticipated over the forecast period encompass AI-driven rna structure prediction, the expansion of rna-targeted oncology pipelines, developments in rna-specific small molecule libraries, enhanced rna binding selectivity and specificity, and the incorporation of multi-omics approaches within rna drug discovery.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

What Drivers Are Guiding Growth Patterns In The RNA Targeting Small Molecule Drug Discovery Market?

The RNA-targeted small-molecule drug discovery market is projected to expand due to the rising occurrence of cancer, genetic disorders, and viral infections. Cancer involves the uncontrolled proliferation of cells within the body. Viral infections are conditions resulting from viruses, which are minute infectious agents capable of replication only within living organism cells. RNA targeting-based drug discovery provides therapeutic solutions for cancer, genetic disorders, and viral infections because these conditions are associated with genes and dysfunctional genetic material, which can be addressed by medications developed through RNA targeting approaches. As an illustration, a report released in February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental body, estimated 20 million new cancer cases and 9.7 million deaths worldwide in 2022. Lung cancer represented the highest incidence with 2.5 million new cases (12.4%), succeeded by female breast cancer at 2.3 million cases (11.6%), colorectal cancer at 1.9 million cases (9.6%), prostate cancer at 1.5 million cases (7.3%), and stomach cancer at 970,000 cases (4.9%). Projections indicate that by 2050, the number of new cancer cases will escalate by 77%, surpassing 35 million each year. Consequently, the rising occurrence of cancer, genetic disorders, and viral infections fuels the expansion of the RNA-targeted small-molecule drug discovery market.

Which Segments Are Driving Activity In The RNA Targeting Small Molecule Drug Discovery Market?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Which Trends Are Influencing The Performance And Direction Of The RNA Targeting Small Molecule Drug Discovery Market?

Prominent entities within the RNA-targeting small-molecule drug discovery market are implementing advanced platforms, including software-as-a-service (SaaS) models, to achieve a competitive advantage. SaaS functions as a software delivery system, wherein external providers host applications, making them accessible to users via the internet. An example of this is the launch of AIDDISSON by Merck & Co. Inc., a US-based science and technology firm, in December 2023. This platform provides recommendations for the optimal synthesis pathways of selected medications. Such an innovative methodology promises substantial cost reductions in drug discovery and considerably improves the success rate of bringing new drugs to patients. Moreover, by connecting virtual molecular design with practical manufacturing capabilities, the platform enhances the likelihood of delivering innovative treatments to patients, achieving this by uncovering valuable insights from vast datasets. This new AI system amalgamates computer-aided drug design, machine learning, and generative AI to expedite the overall medication development timeline.

Which Leading Companies Dominate The RNA Targeting Small Molecule Drug Discovery Market Share?

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

How Does The RNA Targeting Small Molecule Drug Discovery Market Perform Across Major Global Regions?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized RNA Targeting Small Molecule Drug Discovery Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the rna targeting small molecule drug discovery market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the RNA Targeting Small Molecule Drug Discovery Market be in 2030 compared with 2026?

The rna targeting small molecule drug discovery market has witnessed significant expansion over recent years. It is projected to increase from $2.13 billion in 2025 to $2.6 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.3%. This historical growth can be attributed to several factors including the constrained druggability of protein targets, the increasing occurrence of genetic disorders, breakthroughs in rna biology research, an escalation in academic-industry partnerships, and the initial successful outcomes of rna-based therapeutics.

The rna targeting small molecule drug discovery market is projected for rapid expansion in the coming years, reaching $6.04 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 23.5%. This projected growth during the forecast period is fueled by several factors, including AI-enabled rna target identification, rising investments in precision medicine, the broadening of rna therapeutics pipelines, advancements in rna delivery technologies, and favorable regulatory backing for new modalities. Key trends anticipated over the forecast period encompass AI-driven rna structure prediction, the expansion of rna-targeted oncology pipelines, developments in rna-specific small molecule libraries, enhanced rna binding selectivity and specificity, and the incorporation of multi-omics approaches within rna drug discovery.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

What Drivers Are Guiding Growth Patterns In The RNA Targeting Small Molecule Drug Discovery Market?

The RNA-targeted small-molecule drug discovery market is projected to expand due to the rising occurrence of cancer, genetic disorders, and viral infections. Cancer involves the uncontrolled proliferation of cells within the body. Viral infections are conditions resulting from viruses, which are minute infectious agents capable of replication only within living organism cells. RNA targeting-based drug discovery provides therapeutic solutions for cancer, genetic disorders, and viral infections because these conditions are associated with genes and dysfunctional genetic material, which can be addressed by medications developed through RNA targeting approaches. As an illustration, a report released in February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental body, estimated 20 million new cancer cases and 9.7 million deaths worldwide in 2022. Lung cancer represented the highest incidence with 2.5 million new cases (12.4%), succeeded by female breast cancer at 2.3 million cases (11.6%), colorectal cancer at 1.9 million cases (9.6%), prostate cancer at 1.5 million cases (7.3%), and stomach cancer at 970,000 cases (4.9%). Projections indicate that by 2050, the number of new cancer cases will escalate by 77%, surpassing 35 million each year. Consequently, the rising occurrence of cancer, genetic disorders, and viral infections fuels the expansion of the RNA-targeted small-molecule drug discovery market.

Which Segments Are Driving Activity In The RNA Targeting Small Molecule Drug Discovery Market?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Which Trends Are Influencing The Performance And Direction Of The RNA Targeting Small Molecule Drug Discovery Market?

Prominent entities within the RNA-targeting small-molecule drug discovery market are implementing advanced platforms, including software-as-a-service (SaaS) models, to achieve a competitive advantage. SaaS functions as a software delivery system, wherein external providers host applications, making them accessible to users via the internet. An example of this is the launch of AIDDISSON by Merck & Co. Inc., a US-based science and technology firm, in December 2023. This platform provides recommendations for the optimal synthesis pathways of selected medications. Such an innovative methodology promises substantial cost reductions in drug discovery and considerably improves the success rate of bringing new drugs to patients. Moreover, by connecting virtual molecular design with practical manufacturing capabilities, the platform enhances the likelihood of delivering innovative treatments to patients, achieving this by uncovering valuable insights from vast datasets. This new AI system amalgamates computer-aided drug design, machine learning, and generative AI to expedite the overall medication development timeline.

Which Leading Companies Dominate The RNA Targeting Small Molecule Drug Discovery Market Share?

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

How Does The RNA Targeting Small Molecule Drug Discovery Market Perform Across Major Global Regions?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized RNA Targeting Small Molecule Drug Discovery Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the rna targeting small molecule drug discovery market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the RNA Targeting Small Molecule Drug Discovery Market be in 2030 compared with 2026?

The rna targeting small molecule drug discovery market has witnessed significant expansion over recent years. It is projected to increase from $2.13 billion in 2025 to $2.6 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.3%. This historical growth can be attributed to several factors including the constrained druggability of protein targets, the increasing occurrence of genetic disorders, breakthroughs in rna biology research, an escalation in academic-industry partnerships, and the initial successful outcomes of rna-based therapeutics.

The rna targeting small molecule drug discovery market is projected for rapid expansion in the coming years, reaching $6.04 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 23.5%. This projected growth during the forecast period is fueled by several factors, including AI-enabled rna target identification, rising investments in precision medicine, the broadening of rna therapeutics pipelines, advancements in rna delivery technologies, and favorable regulatory backing for new modalities. Key trends anticipated over the forecast period encompass AI-driven rna structure prediction, the expansion of rna-targeted oncology pipelines, developments in rna-specific small molecule libraries, enhanced rna binding selectivity and specificity, and the incorporation of multi-omics approaches within rna drug discovery.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

What Drivers Are Guiding Growth Patterns In The RNA Targeting Small Molecule Drug Discovery Market?

The RNA-targeted small-molecule drug discovery market is projected to expand due to the rising occurrence of cancer, genetic disorders, and viral infections. Cancer involves the uncontrolled proliferation of cells within the body. Viral infections are conditions resulting from viruses, which are minute infectious agents capable of replication only within living organism cells. RNA targeting-based drug discovery provides therapeutic solutions for cancer, genetic disorders, and viral infections because these conditions are associated with genes and dysfunctional genetic material, which can be addressed by medications developed through RNA targeting approaches. As an illustration, a report released in February 2024 by the World Health Organization (WHO), a Switzerland-based intergovernmental body, estimated 20 million new cancer cases and 9.7 million deaths worldwide in 2022. Lung cancer represented the highest incidence with 2.5 million new cases (12.4%), succeeded by female breast cancer at 2.3 million cases (11.6%), colorectal cancer at 1.9 million cases (9.6%), prostate cancer at 1.5 million cases (7.3%), and stomach cancer at 970,000 cases (4.9%). Projections indicate that by 2050, the number of new cancer cases will escalate by 77%, surpassing 35 million each year. Consequently, the rising occurrence of cancer, genetic disorders, and viral infections fuels the expansion of the RNA-targeted small-molecule drug discovery market.

Which Segments Are Driving Activity In The RNA Targeting Small Molecule Drug Discovery Market?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

3) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

4) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Which Trends Are Influencing The Performance And Direction Of The RNA Targeting Small Molecule Drug Discovery Market?

Prominent entities within the RNA-targeting small-molecule drug discovery market are implementing advanced platforms, including software-as-a-service (SaaS) models, to achieve a competitive advantage. SaaS functions as a software delivery system, wherein external providers host applications, making them accessible to users via the internet. An example of this is the launch of AIDDISSON by Merck & Co. Inc., a US-based science and technology firm, in December 2023. This platform provides recommendations for the optimal synthesis pathways of selected medications. Such an innovative methodology promises substantial cost reductions in drug discovery and considerably improves the success rate of bringing new drugs to patients. Moreover, by connecting virtual molecular design with practical manufacturing capabilities, the platform enhances the likelihood of delivering innovative treatments to patients, achieving this by uncovering valuable insights from vast datasets. This new AI system amalgamates computer-aided drug design, machine learning, and generative AI to expedite the overall medication development timeline.

Which Leading Companies Dominate The RNA Targeting Small Molecule Drug Discovery Market Share?

Major companies operating in the rna targeting small molecule drug discovery market are F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb Company, Moderna Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics, Arbutus Biopharma Corporation, Arbutus Biopharma Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

How Does The RNA Targeting Small Molecule Drug Discovery Market Perform Across Major Global Regions?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2025. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized RNA Targeting Small Molecule Drug Discovery Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2026, By The Business Research Company

Rna Targeting Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Small Molecule Drug Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the rna targeting small molecule drug discovery market from 2025–2034 with trusted insights from The Business Research Company

How Is The RNA Targeting Small Molecule Drug Discovery Market Size Expected To Expand Over 2029-2034?

The RNA targeting small molecule drug discovery market has experienced rapid expansion in recent years. This market is projected to expand from $1.76 billion in 2024 to $2.13 billion in 2025, achieving a compound annual growth rate (CAGR) of 20.8%. Historically, the market’s growth has been fueled by an increased understanding of disease genetics, genomic and proteomic discoveries, drug resistance challenges, investment in biotechnology and pharmaceutical research, and the rise of RNA therapeutics.

The RNA targeting small molecule drug discovery market is poised for significant expansion in the foreseeable future. It is projected to achieve a valuation of $4.85 billion by 2029, growing at a robust compound annual growth rate (CAGR) of 22.9%. This anticipated growth during the forecast period stems from factors such as the broadening of RNA epigenetics research, advancements in RNA-seq and functional genomics, the incorporation of artificial intelligence (AI), patient-focused strategies, and exosome-delivered therapeutics. Significant trends anticipated in this period encompass the development of RNA editing technologies, progress in CRISPR technology, various technological breakthroughs, enhancements in RNA biology understanding, and the application of RNA targeting specifically for neurodegenerative conditions.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Which Market Factors Are Fueling The RNA Targeting Small Molecule Drug Discovery Industry Growth?

The growing occurrence of cancer, genetic disorders, and viral infections is anticipated to boost the RNA-targeted small-molecule drug discovery market in the coming years. Cancer is characterized by uncontrolled cell growth within the body, while viral infections are caused by minute viruses that can only replicate inside the cells of living organisms. RNA targeting-based drug discovery offers a treatment approach for cancer, genetic disorders, and viral infections, as these conditions are linked to genes and malfunctioning genetic material, which can be addressed using therapies developed through RNA targeting methods. For example, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, published in February 2024, estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). It is projected that new cancer cases will increase by 77% by 2050, reaching over 35 million annually. Consequently, the rising prevalence of cancer, genetic disorders, and viral infections is fueling the growth of the RNA-targeted small-molecule drug discovery market.

Which Categories Are Covered In The RNA Targeting Small Molecule Drug Discovery Market Segmentation Analysis?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies

3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Which Market Trends Are Expected To Define The Future Of The RNA Targeting Small Molecule Drug Discovery Market?

The integration of artificial intelligence (AI) into drug discovery is emerging as a significant development within the small-molecule drug discovery market. Key players in the small molecule drug discovery market are employing AI technology to expedite drug discovery processes, thereby securing their market standing. A notable illustration is Google Cloud, the cloud computing division of the US-based technology company Google, which in May 2023 introduced its Target and Lead Identification Suite and Multiomics Suite to enhance the drug discovery workflow. The Multiomics Suite accelerates the identification and analysis of genetic data, empowering businesses to develop precision medicines, while the Target and Lead Identification Suite assists researchers in improving their understanding of amino acid functions and predicting protein structures.

Which Organizations Are At The Forefront Of The RNA Targeting Small Molecule Drug Discovery Market?

Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Which Geographic Areas Are Driving Strong Demand For The RNA Targeting Small Molecule Drug Discovery Market?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2025, By The Business Research Company

Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-global-market-report

Drug Discovery Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Drug Discovery Informatics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-informatics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model